Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 346 (miR-346)
- Target
- miR-346
- Molecular classification
- MicroRNA, Non-coding RNA, Regulatory RNA
01
Overview
MicroRNA 346 (miR-346) is a small non-coding RNA that regulates gene expression post-transcriptionally, primarily by binding to target mRNAs and affecting their translation or stability[1][2][3][4]. Uniquely, miR-346 has been shown to upregulate the translation of certain genes such as hTERT and receptor-interacting protein 140 by facilitating mRNA association with polysomes in an Ago2-independent manner[1][3]. miR-346 also directly targets genes like AGO2, and its up- or downregulation impacts key cellular processes, including proliferation, apoptosis, and oxidative stress, especially in the context of cancer and retinal diseases[1][2]. Aberrant miR-346 expression has been implicated in tumorigenesis (notably cervical cancer and gliomas), retinal degeneration, and potentially other diseases where gene regulatory balance is disrupted[1][2][4].
- Other names
- MIR346hsa-mir-346miRNA346miR-346MIRN346
02
Mechanism of action
Downregulation or sequestration by antisense oligonucleotides (experimental); Overexpression by miRNA mimics (experimental)
03
Biological functions
Regulation of gene expression (post-transcriptional)Regulation of cell proliferationRegulation of apoptosisRegulation of cell cycleOxidative stress response
04
Disease associations
Cancer (e.g., cervical cancer[1], glioma[4], colorectal cancer[5])Diabetic retinopathy and retinal disease[2]Potential roles in other proliferative and inflammatory diseases
05
Safety considerations
Modulating microRNAs can potentially alter the expression of numerous downstream targets, raising concerns about off-target effects and broad changes in cellular pathways[1][2].
06
Biomarkers
Expression levels of miR-346 can serve as biomarkers for certain cancers (e.g., upregulation in cervical cancer[1], glioma[4], diabetic retinopathy[2])
Beyond the preview
Go deeper on MicroRNA 346 (miR-346).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroRNA 346 (miR-346).